Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19?

Anders Kjellberg, Antonio De Maio, Peter Lindholm, Anders Kjellberg, Antonio De Maio, Peter Lindholm

Abstract

Introduction: SARS-CoV-2 affects part of the innate immune response and activates an inflammatory cascade stimulating the release of cytokines and chemokines, particularly within the lung. Indeed, the inflammatory response during COVID-19 is likely the cause for the development of acute respiratory distress syndrome (ARDS). Patients with mild symptoms also show significant changes on pulmonary CT-scan suggestive of severe inflammatory involvement.

Hypothesis: The overall hypothesis is that HBO2 is safe and reduces the inflammatory response in COVID-19 pneumonitis by attenuation of the innate immune system, increase hypoxia tolerance and thereby prevent organ failure and reduce mortality.

Evaluation of the hypothesis: HBO2 is used in clinical practice to treat inflammatory conditions but has not been scientifically evaluated for COVID-19. Experimental and empirical data suggests that HBO2 may reduce inflammatory response in COVID-19. However, there are concerns regarding pulmonary safety in patients with pre-existing viral pneumonitis.

Empirical data: Anecdotes from "compassionate use" and two published case reports show promising results.

Consequences of the hypothesis and discussion: Small prospective clinical trials are on the way and we are conducting a randomized clinical trial.

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

References

    1. Perlman S., Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7:439–450.
    1. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529–539.
    1. Drescher B., Bai F. Neutrophil in viral infections, friend or foe? Virus Res. 2013;171:1–7.
    1. Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7:11.
    1. Wilson J.G., Calfee C.S. ARDS subphenotypes: understanding a heterogeneous syndrome. Critical care (London, England) 2020;24:102.
    1. Zhang H., Zhou P., Wei Y., Yue H., Wang Y., Hu M. Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19. Ann Intern Med. 2020
    1. Pan F., Ye T., Sun P., Gui S., Liang B., Li L. Novel coronavirus (COVID-19) pneumonia. Radiology. 2019;2020
    1. Arabi Y.M., Murthy S., Webb S. COVID-19: a novel coronavirus and a novel challenge for critical care. Intensive Care Med. 2020
    1. Ledford H. Hopes rise for coronavirus drug remdesivir. Nature. 2020
    1. Gill A.L., Bell C.N. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. QJM. 2004;97:385–395.
    1. Thom S.R. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg. 2011;127(Suppl 1):131S–141S.
    1. Bennett M.H., Feldmeier J., Hampson N.B., Smee R., Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. Cochr Database Systemat Rev. 2016;4:CD005005.
    1. Oscarsson N., Muller B., Rosen A., Lodding P., Molne J., Giglio D. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial. Lancet Oncol. 2019
    1. Kirby J.P. Hyperbaric oxygen therapy and radiation-induced injuries. Mo Med. 2019;116:198–200.
    1. Kirby J.P. Hyperbaric oxygen indications: diabetic foot ulcers and intractable management. Mo Med. 2019;116:188–191.
    1. Han C.H., Zhang P.X., Xu W.G., Li R.P., Xu J.J., Liu W.W. Polarization of macrophages in the blood after decompression in mice. Med Gas Res. 2017;7:236–240.
    1. Geng M., Zhou L., Liu X., Li P. Hyperbaric oxygen treatment reduced the lung injury of type II decompression sickness. Int J Clin Exp Pathol. 2015;8:1797–1803.
    1. Buras J.A., Holt D., Orlow D., Belikoff B., Pavlides S., Reenstra W.R. Hyperbaric oxygen protects from sepsis mortality via an interleukin-10-dependent mechanism. Crit Care Med. 2006;34:2624–2629.
    1. Oyaizu T., Enomoto M., Yamamoto N., Tsuji K., Horie M., Muneta T. Hyperbaric oxygen reduces inflammation, oxygenates injured muscle, and regenerates skeletal muscle via macrophage and satellite cell activation. Sci Rep. 2018;8:1288.
    1. Benson R.M., Minter L.M., Osborne B.A., Granowitz E.V. Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages. Clin Exp Immunol. 2003;134:57–62.
    1. Dong H., Li J., Lv Y., Zhou Y., Wang G., Hu S. Comparative analysis of the alveolar macrophage proteome in ALI/ARDS patients between the exudative phase and recovery phase. BMC Immunol. 2013;14:25.
    1. De Maio A., Hightower L.E. COVID-19, acute respiratory distress syndrome (ARDS) and hyperbaric oxygen therapy (HBOT): what is the link? Cell Stress Chaperones. 2020;(May 18):1–4. doi: 10.1007/s12192-020-01121-0.
    1. Tezgin D., Giardina C., Perdrizet G.A., Hightower L.E. The effect of hyperbaric oxygen on mitochondrial and glycolytic energy metabolism: the caloristasis concept. Cell Stress Chaperones. 2020;25(4):667–677. doi: 10.1007/s12192-020-01100-5.
    1. Edremitlioglu M., Kilic D., Oter S., Kisa U., Korkmaz A., Coskun O. The effect of hyperbaric oxygen treatment on the renal functions in septic rats: relation to oxidative damage. Surg Today. 2005;35:653–661.
    1. Buras J.A., Reenstra W.R. Endothelial-neutrophil interactions during ischemia and reperfusion injury: basic mechanisms of hyperbaric oxygen. Neurol Res. 2007;29:127–131.
    1. Yu S.Y., Chiu J.H., Yang S.D., Yu H.Y., Hsieh C.C., Chen P.J. Preconditioned hyperbaric oxygenation protects the liver against ischemia-reperfusion injury in rats. J Surg Res. 2005;128:28–36.
    1. Fuller A.M., Giardina C., Hightower L.E., Perdrizet G.A., Tierney C.A. Hyperbaric oxygen preconditioning protects skin from UV-A damage. Cell Stress Chaperones. 2013;18:97–107.
    1. Harrison L.E., Giardina C., Hightower L.E., Anderson C., Perdrizet G.A. Might hyperbaric oxygen therapy (HBOT) reduce renal injury in diabetic people with diabetes mellitus? From preclinical models to human metabolomics. Cell Stress Chaperones. 2018;23:1143–1152.
    1. Halbach J.L., Prieto J.M., Wang A.W., Hawisher D., Cauvi D.M., Reyes T. Early hyperbaric oxygen therapy improves survival in a model of severe sepsis. Am J Physiol Regul Integr Comp Physiol. 2019;317:R160–R168.
    1. Thom S.R., Lauermann M.W., Hart G.B. Intermittent hyperbaric oxygen therapy for reduction of mortality in experimental polymicrobial sepsis. J Infect Dis. 1986;154:504–510.
    1. Weislow O.S., Pakman L.M. Inhibition of Pseudomonas aeruginosa by hyperbaric oxygen: interaction with mouse peritoneal exudate cells. Infect Immun. 1974;10:546–552.
    1. Lin H.C., Wan F.J., Wu C.C., Tung C.S., Wu T.H. Hyperbaric oxygen protects against lipopolysaccharide-stimulated oxidative stress and mortality in rats. Eur J Pharmacol. 2005;508:249–254.
    1. Pedoto A., Nandi J., Yang Z.J., Wang J., Bosco G., Oler A. Beneficial effect of hyperbaric oxygen pretreatment on lipopolysaccharide-induced shock in rats. Clin Exp Pharmacol Physiol. 2003;30:482–488.
    1. Thom S.R. Oxidative stress is fundamental to hyperbaric oxygen therapy. J Appl Physiol. 1985;2009(106):988–995.
    1. Guerard S., Holmdahl R., Wing K. Reactive oxygen species regulate innate but not adaptive inflammation in ZAP70-mutated SKG arthritic mice. Am J Pathol. 2016
    1. Novak S., Drenjancevic I., Vukovic R., Kellermayer Z., Cosic A., Tolusic Levak M. Anti-inflammatory effects of hyperbaric oxygenation during DSS-induced colitis in BALB/c mice include changes in gene expression of HIF-1alpha, proinflammatory cytokines, and antioxidative enzymes. Mediators Inflamm. 2016;2016:7141430.
    1. Salhanick S.D., Belikoff B., Orlow D., Holt D., Reenstra W., Buras J.A. Hyperbaric oxygen reduces acetaminophen toxicity and increases HIF-1alpha expression. Acad Emerg Med. 2006;13:707–714.
    1. Anguiano-Hernandez YM, Contreras-Mendez L, de Los Angeles Hernandez-Cueto M, Muand Oz-Medina JE, Santillan-Verde MA, Barbosa-Cabrera RE, Delgado-Quintana CA, Trejo-Rosas S, Santacruz-Tinoco CE, Gonzalez-Ibarra J, Gonzalez-Bonilla CR. Modification of HIF-1alpha, NF-akappaB, IGFBP-3, VEGF and adiponectin in diabetic foot ulcers treated with hyperbaric oxygen. Undersea Hyperb Med 2019; 46: 35-44.
    1. Godman C.A., Chheda K.P., Hightower L.E., Perdrizet G., Shin D.G., Giardina C. Hyperbaric oxygen induces a cytoprotective and angiogenic response in human microvascular endothelial cells. Cell Stress Chaperones. 2010;15:431–442.
    1. Lisagors I.L., Sondore A., Pupelis G., Oshs P., Iaunalksne I., Pavars M. Impact of hyperbaric oxygen therapy on the clinical course of acute pancreatitis and systemic inflammation response syndrome. Anesteziol Reanimatol. 2008:34–38.
    1. Dulai P.S., Buckey J.C., Jr., Raffals L.E., Swoger J.M., Claus P.L., O'Toole K. Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. Am J Gastroenterol. 2018
    1. Kallet R.H., Branson R.D. Should oxygen therapy be tightly regulated to minimize hyperoxia in critically ill patients? Respiratory Care. 2016;61:801–817.
    1. Heyboer M., 3rd, Sharma D., Santiago W., McCulloch N. Hyperbaric oxygen therapy: side effects defined and quantified. Adv Wound Care (New Rochelle) 2017;6:210–224.
    1. Wingelaar T.T., van Ooij P.A.M., van Hulst R.A. Oxygen toxicity and special operations forces diving: hidden and dangerous. Front Psychol. 2017;8:1263.
    1. Chavko M., Mahon R.T., McCarron R.M. Mechanisms of protection against pulmonary hyperbaric O(2) toxicity by intermittent air breaks. Eur J Appl Physiol. 2008;102:525–532.
    1. Zhang L., Zhang Y., Wang Z., Chen Y., Li R. Intermittent hyperbaric oxygen exposure mobilizing peroxiredoxin 6 to prevent oxygen toxicity. J Physiol Sci. 2019;69:779–790.
    1. Moon R.D., Weaver L.K. Hyperbaric oxygen as a treatment for COVID-19 infection? Undersea Hyperb Med. 2020;47:177–179.
    1. Guo D., Pan S., Wang M., Guo Y. Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports. Undersea Hyperb Med. 2020;47:181–187.
    1. Thibodeaux K., Speyrer M., Raza A., Yaakov R., Serena T.E. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. J Wound Care. 2020;29:S4–S8.
    1. Bessereau J., Aboab J., Hullin T., Huon-Bessereau A., Bourgeois J.L., Brun P.M. Safety of hyperbaric oxygen therapy in mechanically ventilated patients. Int Marit Health. 2017;68:46–51.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe